- Home
- FRD vs KLRS Comparison
FRD vs KLRS Comparison
Compare FRD & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FRD | KLRS |
|---|---|---|
| Founded | 1965 | 2019 |
| Country | United States | United States |
| Employees | N/A | 20 |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.3M | 132.8M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | FRD | KLRS |
|---|---|---|
| Price | $18.62 | $5.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $20.67 |
| AVG Volume (30 Days) | 24.4K | ★ 63.1K |
| Earning Date | 02-09-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $121,157,278.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.90 | ★ N/A |
| Revenue Growth | ★ 55.82 | N/A |
| 52 Week Low | $14.01 | $2.14 |
| 52 Week High | $24.37 | $11.88 |
Technical Indicators
Market Signals| Indicator | FRD | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 57.65 | 35.64 |
| Support Level | $18.15 | $4.35 |
| Resistance Level | $18.73 | $7.20 |
| Average True Range (ATR) | 0.70 | 0.64 |
| MACD | 0.18 | 0.11 |
| Stochastic Oscillator | 76.17 | 29.47 |
Price Performance
Historical ComparisonAbout FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.